PCOR insider sales: O'Connor disposes 15,384 shares via 10b5-1
Rhea-AI Filing Summary
Kevin J. O'Connor, a director of Procore Technologies (PCOR), reported scheduled sales of company stock under a prearranged 10b5-1 plan. The filings show dispositions on 09/16/2025 and 09/17/2025: 7,692 shares sold at a weighted average price of $70.41 (range $70.05–$70.85), 7,255 shares sold at $72.55 (range $71.80–$72.775), and 437 shares sold at $72.93 (range $72.905–$72.955).
Following the transactions the filing reports indirect beneficial ownership maintained in the Kevin J. O'Connor Revocable Trust U/A DTD 06-13-19, with reported holdings of 1,131,021, then 1,123,766, then 1,123,329 shares after each sale. The Form 4 was signed by attorney-in-fact Benjamin C. Singer on 09/18/2025.
Positive
- Sales executed under a prearranged 10b5-1 plan, indicating scheduled, rule-compliant dispositions
- Transparent disclosure with weighted-average prices and price ranges for each tranche
Negative
- Insider dispositions reduced indirect holdings from 1,131,021 to 1,123,329 shares across the reported sales
- Materiality of the sales is unclear from the filing alone because the company's market capitalization and percent ownership impact are not provided
Insights
TL;DR Insider sales were executed under a prearranged 10b5-1 plan; transactions appear routine and disclosed with weighted-average pricing ranges.
The reported transactions total 15,384 shares sold across 09/16/2025–09/17/2025 in three tranches with weighted average prices of $70.41, $72.55 and $72.93. The filings show the shares are held indirectly in a revocable trust, and the sales reduced indirect holdings from 1,131,021 to 1,123,329 shares across the reported lines. From a trading-impact perspective, these are director-initiated dispositions under an established plan and documented with price ranges; there is no other transaction type or derivative activity reported.
TL;DR Sales were conducted via a disclosed 10b5-1 plan and properly reported on Form 4, indicating adherence to insider-trading protocols.
The filing explicitly states the disposals were made pursuant to a 10b5-1 plan dated November 21, 2024, and provides weighted-average price ranges and the trust holding details. The signature by an attorney-in-fact is included. These elements reflect standard governance procedures for scheduled insider sales and transparent SEC reporting; no unexplained amendments, option exercises, or derivative transactions accompany the disclosure.